Simultaneous targeting of interleukin-1 and interleukin-18 is required for protection against inflammatory and septic shock
© Berghe et al.; licensee BioMed Central Ltd. 2014
Published: 3 December 2014
Sepsis is one of the leading causes of death around the world. The failure of clinical trials to treat sepsis demonstrates that the molecular mechanisms are multiple and still insufficiently understood. The objective is to clarify the long disputed hierarchical contribution of several central inflammatory mediators, namely IL-1β, IL-18, CASP7, CASP1 and CASP11, in septic shock, and to explore their therapeutic potential.
LPS-induced and TNF-induced lethal shock, as well as cecal ligation and puncture (CLP), were performed in genetically or pharmacologically targeted mice. Body temperature and survival were monitored closely, and plasma was analyzed for several markers of cellular disintegration and inflammation.
Interestingly, deficiency of both IL-1β and IL-18 additively prevented LPS-induced mortality. The detrimental role of IL-1β and IL-18 was confirmed in mice subjected to a lethal dose of TNF, or to a lethal CLP procedure. Although their upstream activator, CASP1, and its amplifier, CASP11, are considered potential therapeutic targets because of their crucial involvement in endotoxin-induced toxicity, CASP11 or CASP1/11 deficient mice were not, or hardly, protected against a lethal TNF or CLP challenge. In line with our results obtained in genetically deficient mice, only the combined neutralization of IL-1 and IL-18, using the IL-1 receptor antagonist Anakinra and anti-IL-18 antibodies, conferred complete protection against endotoxin-induced lethality.
Our data point towards the therapeutic potential of neutralizing IL-1 and IL-18 simultaneously in sepsis, rather than inhibiting the upstream inflammatory caspases.
DD and PB contributed equally to this work. AC and PV share senior authorship. The authors are grateful to R Flavell (Howard Hughes Medical Institute, Chevy Chase, USA) and A Zychlinsky (Max Planck Institute, Berlin, Germany) for respectively the CASP1 knockout mice and the IL-1β/IL-18 double knockout mice. They thank B Lambrecht for fruitful discussions. TVB holds a postdoctoral fellowship from the FWO, PB is paid by VIB. Research in the Vandenabeele group is funded by European grants (FP6 ApopTrain, MRTN-CT-035624; FP7 EC RTD Integrated Project, Apo-Sys, FP7-200767; Euregional PACT II), Belgian grants (Interuniversity Attraction Poles, IAP 7/32), Flemish grants (Research Foundation Flanders, FWO G.0875.11, FWO G.0973.11 and FWO G.0A45.12N, FWO G.0787.13N, Methusalem), Ghent University grants (MRP, GROUP-ID consortium), a grant from the Foundation against Cancer, F94 and grants from Flanders Institute for Biotechnology (VIB). PV holds a Methusalem grant (BOF09/01M00709) from the Flemish Government. The authors declare no conflict of interest.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.